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1. INTRODUCTION {#jcla22838-sec-0005}
===============

*Klebsiella pneumoniae* is one of the most important pathogens responsible for bloodstream infections, second only to *Escherichia coli*.[1](#jcla22838-bib-0001){ref-type="ref"}, [2](#jcla22838-bib-0002){ref-type="ref"} Recently, a new variant termed hypervirulent *K pneumoniae*(hvKP) has been reported in Taiwan.[3](#jcla22838-bib-0003){ref-type="ref"} Compared with classic *K pneumoniae* (cKP), hvKP is characterized by the hypermucoviscous phenotype and hypervirulent factors. Alarmingly, hvKP strains are capable of inducing severe, invasive, community‐acquired infection in immunocompetent individuals with a propensity for causing metastatic spread to distant sites, which constitutes a serious threat to public health.

The *pks*gene cluster, originally identified in extraintestinal pathogenic *E coli*,[4](#jcla22838-bib-0004){ref-type="ref"} encodes enzymes responsible for the synthesis of colibactin, a genotoxin that has been shown to induce double‐strand DNA breaks, cell cycle arrest, and cell death and contribute to increased virulence. It was shown that the presence of the *pks* genes is strongly correlated with bacteremia in *E coli*.[5](#jcla22838-bib-0005){ref-type="ref"} In a mouse model of septicemia, the colibactin‐producing *E coli* strains were reported to be associated with significantly lower survival rate.[6](#jcla22838-bib-0006){ref-type="ref"} Several studies showed that inactivation of *pks* genes reduce the ability of *E coli* strains to colonize the intestinal tract and consequently to translocate to the blood.[7](#jcla22838-bib-0007){ref-type="ref"}, [8](#jcla22838-bib-0008){ref-type="ref"} Recently, the *pks*gene cluster was also found in *K pneumoniae*. It was reported that *pks*‐encoding colibactin was related to the *K pneumoniae* hypervirulence in meningitis model.[9](#jcla22838-bib-0009){ref-type="ref"} On the basis of these researches, we speculated that there may be a potential correlation between the *pks* gene cluster, virulence, and *K pneumoniae*‐induced bloodstream infections (BSIs). However, little reports are available regarding the characteristics of *K pneumonia*bloodstream strains caused by hvKP, and even less focused on colibactin‐producing *K pneumoniae*. Thus, the aim of this study was to investigate the prevalence of the *pks* gene cluster, and clinical and molecular characteristics of *K pneumoniae*‐induced BSIs.

2. MATERIALS AND METHODS {#jcla22838-sec-0006}
========================

2.1. Isolates {#jcla22838-sec-0007}
-------------

A total of 190non‐repetitive *K pneumonia*bloodstream isolates were collected from March 2016 to March 2018. Relevant clinical data were also retrieved. The detection of *K pneumoniae*in blood cultures within 48 hours after admission was defined as community‐acquired BSIs. Correspondingly, the development of bacteremia over 48 hours into inpatient admission was defined as hospital‐acquired BSIs, including infections correlated with the presence of medical devices.[10](#jcla22838-bib-0010){ref-type="ref"}, [11](#jcla22838-bib-0011){ref-type="ref"} The primary site of BSIs was identified if a localized infection was present before or coincident with the detection of bacteremia.[12](#jcla22838-bib-0012){ref-type="ref"} Laboratory data were obtained on the day of the first positive episode isolated from blood.

2.2. Detection of the *pks* gene cluster, capsular types, and virulence genes {#jcla22838-sec-0008}
-----------------------------------------------------------------------------

The presence of *pks* gene cluster, capsular types, and virulence genes were detected by polymerase chain reaction (PCR) as previously described.[13](#jcla22838-bib-0013){ref-type="ref"} Genomic DNA of *K pneumonia* was extracted by boiling method. Briefly, 3‐5 colonies from an overnight culture of *K pneumonia* was suspended in 200 μL of sterile distilled water and boiled at 95°C for 10 minutes and then centrifuged at 13 000 *g* for 10 minutes to remove cellular debris. The supernatant was used as template for amplifications. The PCR products were visualized by 1% agarose gel electrophoresis. Strains positive for *p‐rmpA* and *iucA* were designated as hvKP. For *pks*‐positive strains that were negative for K1, K2, K5, K20, K54, and K57, their capsular types were identified by PCR amplification and sequencing of *wzi* gene as previously described.[14](#jcla22838-bib-0014){ref-type="ref"} The primers used in this study are listed in Table [1](#jcla22838-tbl-0001){ref-type="table"}.

###### 

Primers used in this study

  Primer name                                   DNA sequence (5′‐3′)                 Amplicon size (bp)
  --------------------------------------------- ------------------------------------ --------------------
  Capsular serotypes                                                                 
  K1                                            F: GGTGCTCTTTACATCATTGC              1283
  R:GCAATGGCCATTTGCGTTAG                                                             
  K2                                            F:GACCCGATATTCATACTTGACAGAG          641
  R:CCTGAAGTAAAATCGTAAATAGATGGC                                                      
  K5                                            F:TGGTAGTGATGCTCGCGA                 741
  R:CCTGAACCCACCCCAATC                                                               
  K20                                           F:CGGTGCTACAGTGCATCATT               280
  R:GTTATACGATGCTCAGTCGC                                                             
  K54                                           F:CATTAGCTCAGTGGTTGGCT               881
  R:GCTTGACAAACACCATAGCAG                                                            
  K57                                           F:CTCAGGGCTAGAAGTGTCAT               1037
  R:CACTAACCCAGAAAGTCGAG                                                             
  *Wzi*                                         F:GTGCCGCGAGCGCTTTCTATCTTGGTA TTCC   580
  R:GAGAGCCACTGGTTCCAGAA\[C/T\]TT\[C/G\]ACCGC                                        
  Virulence genes                                                                    
  *p‐rmpA*                                      F:CATAAGAGTATTGGTTGACAG              461
  R:CTTGCATGAGCCATCTTTCA                                                             
  *wcaG*                                        F: GGTTGGKTCAGCAATCGTA               169
  R:ACTATTCCGCCAACTTTTGC                                                             
  *mrkD*                                        F:AAGCTATCGCTGTACTTCCGGCA            340
  R:GGCGTTGGCGCTCAGATAGG                                                             
  *allS*                                        F:CATTACGCACCTTTGTCAGC               764
  R:GAATGTGTCGGCGATCAGCTT                                                            
  *ybtS*                                        F:GACGGAAACAGCACGGTAAA               242
  R:GAGCATAATAAGGCGAAAGA                                                             
  *kfu*                                         F:GGCCTTTGTCCAGAGCTACG               638
  R:GGGTCTGGCGCAGAGTATGC                                                             
  *iucA*                                        F:GCATAGGCGGATACGAACAT               556
  R:CACAGGGCAATTGCTTACCT                                                             
  *Pks* gene cluster                                                                 
  *clbA*                                        F:CTAGATTATCCGTGGCGATTC              1311
  R:CAGATACACAGATACCATTCA                                                            
  *clbB*                                        F:GATTTGGATACTGGCGATAACCG            579
  R:CCATTTCCCGTTTGAGCACAC                                                            
  *clbN*                                        F:GTTTTGCTCGCCAGATAGTCATTC           733
  R:CAGTTCGGGTATGTGTGGAAGG                                                           
  *clbQ*                                        F:CTTGTATAGTTACACAACTATTTC           821
  R:TTATCCTGTTAGCTTTCGTTC                                                            
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2.3. Antimicrobial susceptibility testing {#jcla22838-sec-0009}
-----------------------------------------

Antimicrobial susceptibility testing was carried out by bioMerieux VITEK‐2 (bioMerieux). The minimum inhibitory concentrations (MICs) of antimicrobial agents were interpreted according to the guidelines established by the Clinical and Laboratory Standards Institute (CLSI).[15](#jcla22838-bib-0015){ref-type="ref"} A panel of 20 antimicrobial agents was tested, including ampicillin‐sulbactam, piperacillin‐tazobactam, cefoperazone‐sulbactam, cefazolin, cefuroxime, ceftazidime, ceftriaxone, cefepime, cefotan, aztreonam, ertapenem, imipenem, meropenem, tobramycin, amikacin, gentamicin, levofloxacin, ciprofloxacin, trimethoprim‐sulfamethoxazole, and furantoin. *K pneumoniae* ATCC 700603 and *Staphylococcus aureus*ATCC 25923 were included in each experiment as controls.

2.4. Statistical analysis {#jcla22838-sec-0010}
-------------------------

Categorical variables were analyzed by using chi‐square test or Fisher\'s exact test. For continuous variables, Student\'s *t* test or the Mann‐Whitney *U* test was used to analyze the data, as appropriate. Logistic regression was employed to identify risk factors for *pks^+^ K pneumoniae*‐induced BSIs. All variables with *P*values\<0.1 were incorporated into a multivariate model using a backward approach. All data analysis was performed by SPSS software (version 25.0). A *P*value \< 0.05 was considered statistically significant.

2.5. Ethics statement {#jcla22838-sec-0011}
---------------------

Permission for collecting the information in the medical records of the patients and the *K pneumoniae* isolates for research purposes was approved by the Ethics Committee of Xiangya Hospital Central South University.

3. RESULTS {#jcla22838-sec-0012}
==========

3.1. Prevalence of *pks* gene cluster, capsular types, and virulence gene distribution {#jcla22838-sec-0013}
--------------------------------------------------------------------------------------

In this study, the colibactin system markers *clbB*and *clbN* were simultaneously detected in 26.8% (51/190) isolates, which were considered as *pks^+^ K pneumoniae*.[5](#jcla22838-bib-0005){ref-type="ref"}, [16](#jcla22838-bib-0016){ref-type="ref"} The results of two additional colibactin genes *clbA*and *clbQ* were consistent with those for *clbB*and *clbN*. A total of 43 isolates tested positive for K1, K2, K5, K20, K54, and K57 capsular types. Capsular types K1, K2, K5, K20, K54, and K57 comprised 4.7% (9/190), 11.6% (22/190), 0.5% (1/190), 1.0% (2/190), 1.0% (2/190), and 3.7% (7/190) of all *K pneumoniae* strains, respectively. Statistical analysis indicated that the positive rates of K1 and K57 capsular types in *pks^+^* strains were significantly higher than the *pks* ^−^ strains (*P* \< 0.05). The capsular type of remaining 25 *pks^+^* isolates was further determined by *wz*i amplification and sequencing. One isolate was PCR‐negative, and the other 24 isolates were identified as K14, K23, K24, K25, K27, K80, and 17 distinct *wzi* allelic types, respectively. The *wz*i sequences are provided in Supplemental Material 1.

Seven virulence genes were detected including *p‐rmpA*,*wcaG*,*mrkD*,*allS*,*ybtS*,*kfu*, and *iucA*. Compared with the *pks* ^−^ strains, the *pks^+^* strains had significantly higher positive rates of all the tested virulence genes (*P* \< 0.05). As determined by positive *p‐rmpA*and *iucA*, 21.6% (41/190) of *K pneumoniae* bloodstream isolates were hvKP. The *pks*‐positive rate was significantly higher than *pks*‐negative rate among hvKP isolates. More details regarding virulence factors are shown in Table [2](#jcla22838-tbl-0002){ref-type="table"}.

###### 

Capsular types and virulence gene distribution of *pks*‐positive and *pks‐*negative *K pneumoniae*bloodstream isolates

  Virulence factors   *pks*‐positive isolates (n = 51)   *pks‐*negative isolates (n = 139)   *P* value
  ------------------- ---------------------------------- ----------------------------------- ------------------------------------------------
  Capsular types                                                                             
  K1                  9 (17.6%)                          0                                   0.000[\*](#jcla22838-note-0001){ref-type="fn"}
  K2                  7 (13.7%)                          15 (10.8%)                          0.575
  K5                  0                                  1 (0.7%)                            1.000
  K20                 2 (3.9%)                           0                                   0.071
  K54                 2 (3.9%)                           0                                   0.071
  K57                 6 (11.8%)                          1 (0.7%)                            0.000[\*](#jcla22838-note-0001){ref-type="fn"}
  Virulence genes                                                                            
  *p‐rmpA*            30 (58.8%)                         21 (15.1%)                          0.000[\*](#jcla22838-note-0001){ref-type="fn"}
  *wcaG*              20 (39.2%)                         4 (2.8%)                            0.000[\*](#jcla22838-note-0001){ref-type="fn"}
  *mrkD*              51 (100%)                          125 (89.9%)                         0.019[\*](#jcla22838-note-0001){ref-type="fn"}
  *allS*              38 (74.5%)                         52 (37.4%)                          0.000[\*](#jcla22838-note-0001){ref-type="fn"}
  *ybtS*              41 (80.4%)                         65 (47.0%)                          0.000[\*](#jcla22838-note-0001){ref-type="fn"}
  *kfu*               21 (41.2%)                         25 (18.0%)                          0.001[\*](#jcla22838-note-0001){ref-type="fn"}
  *iucA*              32 (62.7%)                         23 (16.5%)                          0.000[\*](#jcla22838-note-0001){ref-type="fn"}
  HvKP                28 (54.9%)                         13 (9.4%)                           0.000[\*](#jcla22838-note-0001){ref-type="fn"}

A *P* value \< 0.05 was considered to be statistically significant.
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3.2. Antimicrobial resistance of *pks* ^+^ and *pks* ^−^ *K pneumoniae* bloodstream isolates {#jcla22838-sec-0014}
--------------------------------------------------------------------------------------------

Overall, the *pks^+^* *K pneumoniae* isolates displayed lower resistance to all tested antimicrobial agents than the *pks* ^−^ strains. In detail, the *pks^+^* *K pneumoniae* isolates were significantly more susceptible to piperacillin‐tazobactam, cefoperazone‐sulbactam, cefazolin, ceftriaxone, aztreonam, ertapenem, meropenem, imipenem, levofloxacin, ciprofloxacin, and furantoin (*P* \< 0.05). A summary of the results is shown in Table [3](#jcla22838-tbl-0003){ref-type="table"}.

###### 

Antimicrobial resistance of *pks*‐positive and *pks‐*negative *K pneumoniae*bloodstream isolates

  Antimicrobial agent             *pks*‐positive isolates (n = 51)   *pks‐*negative isolates (n = 139)   *P* value
  ------------------------------- ---------------------------------- ----------------------------------- ------------------------------------------------
  Ampicillin‐sulbactam            20 (39.2%)                         71 (51.1%)                          0.097
  Piperacillin‐tazobactam         8 (15.7%)                          46 (33.1%)                          0.013[\*](#jcla22838-note-0002){ref-type="fn"}
  Cefoperazone‐sulbactam          10 (19.6%)                         51 (36.7%)                          0.017[\*](#jcla22838-note-0002){ref-type="fn"}
  Cefazolin                       19 (37.3%)                         79 (56.8%)                          0.008[\*](#jcla22838-note-0002){ref-type="fn"}
  Cefuroxime                      17 (33.3%)                         48 (34.5%)                          0.766
  Ceftazidime                     14 (27.4%)                         52 (37.4%)                          0.196
  Ceftriaxone                     18 (35.3%)                         71 (51.1%)                          0.032[\*](#jcla22838-note-0002){ref-type="fn"}
  Cefepime                        20 (39.2%)                         59 (42.4%)                          0.508
  Cefotan                         8 (15.7%)                          37 (26.6%)                          0.093
  Aztreonam                       15 (29.4%)                         70 (50.4%)                          0.005[\*](#jcla22838-note-0002){ref-type="fn"}
  Ertapenem                       8 (15.7%)                          49 (35.2%)                          0.006[\*](#jcla22838-note-0002){ref-type="fn"}
  Meropenem                       7 (13.7%)                          45 (32.4%)                          0.007[\*](#jcla22838-note-0002){ref-type="fn"}
  Imipenem                        9 (17.6%)                          47 (33.8%)                          0.022[\*](#jcla22838-note-0002){ref-type="fn"}
  Tobramycin                      10 (19.6%)                         35 (25.2%)                          0.363
  Amikacin                        7 (13.7%)                          33 (23.7%)                          0.110
  Gentamicin                      13 (25.5%)                         48 (34.5%)                          0.186
  Levofloxacin                    8 (15.7%)                          47 (33.8%)                          0.010[\*](#jcla22838-note-0002){ref-type="fn"}
  Ciprofloxacin                   8 (15.7%)                          52 (37.4%)                          0.003[\*](#jcla22838-note-0002){ref-type="fn"}
  Trimethoprim‐sulfamethoxazole   11 (21.6%)                         48 (34.5%)                          0.065
  Furantoin                       13 (26.0%)                         62 (47.0%)                          0.010[\*](#jcla22838-note-0002){ref-type="fn"}

A *P* value \< 0.05 was considered to be statistically significant.
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3.3. Clinical characteristics of *pks* ^+^ and *pks* ^−^ *K pneumoniae* bloodstream isolates {#jcla22838-sec-0015}
--------------------------------------------------------------------------------------------

The clinical characteristics of the *pks^+^* and the *pks* ^−^ isolates are shown in Table [4](#jcla22838-tbl-0004){ref-type="table"}. There was no significant difference in age and sex between the two groups. More *pks^+^* isolates (60.8%, 31/51) than *pks* ^−^ isolates (42.4%, 59/139) were community‐acquired. Individuals with diabetes mellitus and hypertension are more susceptible to the *pks^+^* isolates than the *pks* ^−^ isolates (*P* \< 0.05). There was a trend of more *pks^+^* bloodstream isolates originated from liver abscess, but the difference was not significant. Notably, the lymphocyte counts were significantly lower in the *pks^+^* group than in the *pks* ^−^group (*P* \< 0.05). Multivariate regression analysis found that diabetes mellitus (OR 2.637, 95% CI: 1.001‐6.948) and the carriage of K1 and K20 (OR 4.581, 95% CI: 1.271‐16.521 and OR 11.716, 95% CI: 2.301‐59.643) capsular types were independent risk factors for *pks^+^* *K pneumoniae*‐induced BSIs.

###### 

Clinical characteristics of *pks*‐positive and *pks‐*negative *K pneumoniae*‐induced bloodstream infections

  Characteristics               *pks*‐positive isolates (n = 51)   *pks‐*negative isolates (n = 139)   *P* value
  ----------------------------- ---------------------------------- ----------------------------------- ------------------------------------------------
  Age                           54.3 ± 19.8                        37.7 ± 26.5                         0.099
  Female                        14 (27.5%)                         22 (15.8%)                          0.841
  Acquisition                                                                                          
  Community‐acquired            31 (60.8%)                         59 (42.4%)                          0.000[\*](#jcla22838-note-0004){ref-type="fn"}
  Hospital‐acquired             20 (39.2%)                         80 (57.6%)                          0.000[\*](#jcla22838-note-0004){ref-type="fn"}
  Underlying condition                                                                                 
  Diabetes mellitus             15 (29.4%)                         19 (13.6%)                          0.012[\*](#jcla22838-note-0004){ref-type="fn"}
  Hypertension                  17 (33.3%)                         19 (13.7%)                          0.002[\*](#jcla22838-note-0004){ref-type="fn"}
  Biliary tract disease         3 (5.9%)                           17 (12.2%)                          0.206
  Liver cirrhosis               4 (7.8%)                           4 (2.9%)                            0.131
  Pulmonary infection           7 (13.7%)                          13 (9.3%)                           0.384
  Hematologic diseases          7 (13.7%)                          17 (12.2%)                          0.783
  Cancer                        8 (15.7%)                          23 (16.5%)                          0.846
  Surgery within 30 d           19 (37.3%)                         44 (31.7%)                          0.467
  Chemotherapy within 7 d       8 (15.7%)                          21 (15.1%)                          0.704
  Primary site                                                                                         
  Biliary tract                 2 (3.9%)                           10 (7.2%)                           0.411
  Respiratory tract             29 (56.9%)                         93 (65.5%)                          0.276
  Urinary tract                 5 (9.8%)                           10 (7.2%)                           0.554
  Intra‐abdomen                 5 (9.8%)                           13 (9.4%)                           0.925
  Brain                         2 (3.9%)                           3 (2.2%)                            0.182
  Liver abscess                 3 (5.9%)                           0                                   0.573
  Laboratory data (mean ± SD)                                                                          
  WBC count, ×10^9^/L           8.7 ± 6.6                          10.9 ± 8.9                          0.746
  RBC count, ×10^12^/L          3.2 ± 0.9                          3.1 ± 0.8                           0.051
  HB, g/L                       95.4 ± 28.5                        97.4 ± 26.2                         0.272
  PLT, ×10^9^/L                 119.4 ± 97.4                       105.0 ± 92.4                        0.876
  NEUT count, ×10^9^/L          7.5 ± 6.3                          7.9 ± 7.6                           0.952
  LY count, ×10^9^/L            0.6 ± 0.6                          1.6 ± 1.5                           0.016[\*](#jcla22838-note-0004){ref-type="fn"}

HB, hemoglobin; LY, lymphocyte; NEUT, neutrophile granulocyte; PLT, platelet; RBC, red blood cell; WBC, white blood cell.

A *P* value \<0.05 was considered to be statistically significant.
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4. DISCUSSION {#jcla22838-sec-0016}
=============

This retrospective study was conducted in 190 patients with *K pneumoniae*‐induced BSIs during a 24‐month period from March 2016 to March 2018. It was the first systematic study focusing on the *pks* prevalence of *K pneumoniae* bloodstream isolates. Meanwhile, the clinical and microbiological characteristics were also analyzed in this study.

Currently, there is no absolute definition of hvKP. But it is clear that hypermucoviscosity and iron acquisition systems contributed to the virulence of *K pneumoniae*.[3](#jcla22838-bib-0003){ref-type="ref"}, [17](#jcla22838-bib-0017){ref-type="ref"} Hence, strains positive for *p‐rmpA* and *iucA* were defined as hvKP in the present study. Our investigation indicated that HvKP accounted for 21.6% of *K pneumoniae*‐induced BSIs. In two previous studies conducted in China, the prevalence of hvKP among *K pneumoniae* bloodstream isolates was 31.4% and 36.8%, respectively.[10](#jcla22838-bib-0010){ref-type="ref"}, [18](#jcla22838-bib-0018){ref-type="ref"}

In this study, the prevalence of *pks* gene cluster among *K pneumoniae* bloodstream isolates was 26.8%. To date, there have been few epidemic reports on emerging *pks^+^* *K pneumoniae* in mainland China. In two previous studies conducted in Taiwan, the positive rates of *pks*among *K pneumoniae* isolated from various body sites were reported 25.6% and 16.7%, respectively.[16](#jcla22838-bib-0016){ref-type="ref"}, [19](#jcla22838-bib-0019){ref-type="ref"} In *E coli*, the prevalence of *pks* gene was high, ranging from 31.5% to 58%, and reported to be significantly associated with bacteremia.[5](#jcla22838-bib-0005){ref-type="ref"} Our results revealed that the rates of *pks^+^* among *K pneumoniae* isolates collected from blood were higher than the overall *pks^+^* rate in Taiwan and lower than that in *E coli*.

The capsule is an important virulence factor of *K pneumoniae*. Some capsular serotypes, especially K1, K2, K5, K20, K54, and K57, are recognized as hypervirulent variants of *K pneumoniae*.[3](#jcla22838-bib-0003){ref-type="ref"} The above six capsular serotypes were detected by the PCR, and K2 was the most frequently identified serotypes of *K pneumoniae* bloodstream isolates in this study. The analysis of distribution showed that K1, K2, K5, K20, K54, and K57 were all present among *pks^+^* isolates while the serotypes of *pks* ^−^ isolates were less diverse. Statistical analysis revealed that compared with *pks* ^−^ strains, the rates of K1 and K57 in *pks^+^* strains were significantly higher. In addition, the K1 strains appeared to be associated with the *pks* genes, as all the K1 strains were positive for *pks*. In a word, these results suggested the diverse serotype distribution and potential pathogenicity of *pks^+^* isolates.

Multiple studies emphasized a positive correlation between the presence of virulence genes and *pks^+^* *E coli*.[5](#jcla22838-bib-0005){ref-type="ref"}, [20](#jcla22838-bib-0020){ref-type="ref"}, [21](#jcla22838-bib-0021){ref-type="ref"} Similar results were found in our study. The analysis of virulence factors associated with hvKP showed that the proportion of all these virulence genes in *pks^+^* isolates was significantly higher than that in *pks* ^−^ isolates. The *mrkD* gene was carried by all *pks^+^*isolates. Besides, *rmpA*,*allS*,*ybtS,*and *iucA*, the genes involved in hypermucoviscosity, allantoin metabolism, yersiniabactin, and aerobactin production, were identified in more than half of *pks^+^* isolates. These findings further supported the notion that *pks* genotype may have a relationship with hypervirulent strains. Relevant experiments are needed to figure out whether *pks* gene cluster contributes to virulence directly or serve as a marker for something else involved in pathogenesis.

It is found that *pks^+^* isolates are associated with low antimicrobial resistance. Statistical analysis revealed that *pks^+^* isolates were significantly less resistant to 11 of 20 tested antimicrobial agents than *pks* ^−^ isolates. This circumstance was possibly owing to the fact that *pks^+^* isolates possessed high percentages of hypervirulent serotypes and virulence genes as the acquisition of virulence is usually accompanied by reduced drug resistance. Currently, the emergence of multidrug‐, extremely drug‐, or pan‐drug‐resistant cKP has already become a tough situation in clinical studies.[22](#jcla22838-bib-0022){ref-type="ref"}, [23](#jcla22838-bib-0023){ref-type="ref"}, [24](#jcla22838-bib-0024){ref-type="ref"} Nonetheless, multidrug‐resistant hvKP strains producing extended spectrum β‐lactamase (ESBL) or carbapenemase have also been described.[25](#jcla22838-bib-0025){ref-type="ref"}, [26](#jcla22838-bib-0026){ref-type="ref"} It is noteworthy that the confluence of genotoxicity and drug resistance is also a disturbing situation in future. Epidemiologic surveillance, effective infection control measures, and novel therapeutic measures targeting the virulence factors are needed to prevent insurmountable *K pneumoniae* infections.

The analysis of clinical characteristics showed that *pks^+^* isolates were more frequently encountered in community‐acquired infection. This implied that *pks^+^*isolates may play an important part in community‐acquired infection like hvKP, which is commonly reported as the cause of community‐acquired infections in young people, particularly pyogenic liver abscesses (PLA).[27](#jcla22838-bib-0027){ref-type="ref"}, [28](#jcla22838-bib-0028){ref-type="ref"} The crucial information obtained from laboratory data was a remarkable decrease in lymphocytes among *pks^+^* isolates. In comparison with *pks* ^−^ isolates, the lymphocyte count of *pks^+^* isolates was significantly lower. A similar discovery that production of colibactin by *E coli* induced profound lymphopenia in a mouse model of sepsis was noted by Ingrid et al[5](#jcla22838-bib-0005){ref-type="ref"} We thus speculated that the colibactin generated from *pks^+^ K pneumoniae* may harbor the same genotoxicity to lymphocytes as *E coli*. More data are needed to clarify the mechanism, which may enlighten the invention of therapeutic targets since the prevention of lymphopenia improved survival in sepsis. In accordant with other studies,[19](#jcla22838-bib-0019){ref-type="ref"} underlying disease including diabetes mellitus, and K1 and K20 capsular types were significant risk factors for *pks^+^ K pneumoniae*infections. It is noticeable that all the strains originated from PLA were positive for *pks*, even though there were only three PLA cases in our study. Large number researches are required to corroborate the association between *pks^+^ K pneumoniae* and PLA.

In conclusion, the *pks^+^ K pneumoniae* was prevalent in individuals with bloodstream infections in mainland China. The high rates of hypervirulent determinants among *pks^+^ K pneumoniae*revealed potential pathogenicity of this emerging gene cluster. Diabetes mellitus, and K1 and K20 capsular types were identified as independent risk factors associated with *pks^+^ K pneumoniae*bloodstream infections. This study highlights the significance of clinical awareness and epidemic surveillance of *pks^+^*strains.
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